Press & News
People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
The latest news around the IndiTreat® clinical trial in colorectal cancer patients that met its primary endpoint.
RedEye interview with CEO Fernando Andreu and CSO Ole Thastrup
Ole Thastrup presents at the Virtual RedEye Fight Cancer 2021 meeting January 21st
2cureX appoints new CEO (BioStock)
Key achievements in 2020 – an IndiTreat® Launch year
2020 – Launch Year for IndiTreat (BioStock)
2cureX publishes Q3’20 report (Biostock)
2cureX launches new website
2cureX presents commercial roadmap 2021 – 2023
Get notified on mail, when news or press release is posted on our website